BioSyent logo.png
BioSyent Schedules Q4 and Full Year 2020 Earnings Release for March 17, 2021
11. März 2021 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, March 11, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
Combogesic Package
BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Combination Tablet in Canada Now Available
16. Dezember 2020 09:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the...
BioSyent logo.png
BioSyent Announces Renewal of Normal Course Issuer Bid
11. Dezember 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the...
BioSyent logo.png
BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020
26. November 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2020. Key...
BioSyent logo.png
BioSyent Schedules Q3 and YTD 2020 Earnings Release for November 26, 2020
17. November 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...
FeraMAX(MD) Pd Thérapeutique 150
Biosyent annonce le lancement du nouveau FeraMAX(MD) Pd Thérapeutique 150
05. November 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, 05 nov. 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », « la Société », Bourse de croissance : RX) a le plaisir d’annoncer le lancement de FeraMAXMD Pd Thérapeutique 150,...
FeraMAX® Pd Therapeutic 150
Biosyent Announces Launch of New FeraMAX® Pd Therapeutic 150
05. November 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Therapeutic 150, the first new...
BioSyent logo.png
BioSyent Named to the Growth List Ranking of Canada’s Fastest-Growing Companies for Eighth Consecutive Year
15. Oktober 2020 09:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 15, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been included in the 32nd annual Growth List, the definitive...
BioSyent logo.png
BioSyent Annonce L'Introduction du Nouveau FeraMAX® Pd
05. Oktober 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, 05 oct. 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », « la Société », Bourse de croissance : RX) a le plaisir d’annoncer l’introduction de FeraMAX® Pd, une nouvelle...
BioSyent logo.png
BioSyent Announces Introduction of New FeraMAX® Pd
05. Oktober 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 05, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the introduction of FeraMAX® Pd, a new oral iron supplement...